Mundipharma controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile5 entries
2024
Collaboration with tobacco-owned Vectura
Healthcare professionals condemned Mundipharma’s announced collaboration with Vectura because Vectura was owned by Philip Morris International, a tobacco company.
2019
Mundipharma pays penalties over TARGIN promotional claims
Fine or penalty
Mundipharma paid $302,400 in penalties in response to 24 infringement notices issued by Australia’s Therapeutic Goods Administration. The notices concerned promotional claims about nine TARGIN opioid medicines that the TGA considered misleading, imbalanced, and otherwise inaccurate; payment is not an admission of guilt or liability.
Source excerpt
The payment of an infringement notice is not an admission of guilt or liability.
The notices were issued because the TGA formed the view that Mundipharma had breached the conditions of registration for nine TARGIN medicines, alleging that its advertising to health professionals was misleading, imbalanced and otherwise inaccurate, in breach of the requirements of the Medicines Australia Code of Conduct regarding promotional materials directed to health professionals.
Mundipharma Pty Ltd (Mundipharma) has paid penalties of $302,400 in response to 24 infringement notices issued by the Therapeutic Goods Administration (TGA) within the Department of Health.
2019
Mundipharma fined over Targin advertising
Fine or penalty
Australia’s Therapeutic Goods Administration fined Mundipharma AU$302,400 and issued 24 infringement notices over promotional materials for Targin that the regulator said could encourage opioid prescribing for chronic non-cancer pain. Mundipharma said it disagreed with the decision.
Company response
Clarification — Mundipharma
A spokesperson for Mundipharma said the sentence that the TGA found fault with was intended to “proactively and voluntarily urge caution when healthcare professionals chose to prescribe an opioid,” adding that Mundipharma “respectfully disagrees” with the regulator’s decision but “respects the important role of the TGA” in pharma regulation.
Source excerpt
The notices were tied to a single sentence that appeared in promotional materials for Targin, which the TGA said “appeared to positively encourage the prescription of Targin medicines for chronic non-cancer pain.”
The Therapeutic Goods Administration (TGA) said in a statement last week that it fined Mundipharma—a group of companies owned by the Sackler family, which also owns Purdue—AU$302,400 ($209,369) and served the company with 24 infringement notices.
Criticism of opioid marketing in Europe
Mundipharma was criticized for allegedly applying marketing approaches similar to those associated with Purdue Pharma when promoting opioids in European markets.
Nyxoid pricing controversy
The company’s Nyxoid naloxone product was criticized over its pricing and because of Purdue-related ownership connections during the opioid crisis.